{"entity":{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","aka":["Kartos Therapeutics, Inc."],"tldr":"Kartos Therapeutics is a United States-based biotechnology company running 3 late-stage cancer trials of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer and diffuse large B-cell lymphoma.","summary":"Kartos Therapeutics, based in Redwood City, the United States, is a biotechnology company. Kartos Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapeutics for patients with cancer. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT05797831 (Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer), plans to enrol 268 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.kartosthera.com"},{"label":"ClinicalTrials.gov: trials led by Kartos Therapeutics","url":"https://clinicaltrials.gov/search?lead=Kartos%20Therapeutics%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["myeloproliferative-neoplasms","endometrial","dlbcl","cll","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["krt-232"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05797831","nct04502394","nct03669965"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Redwood City","country":"US","companyType":"biotech","website":"https://www.kartosthera.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/kartos-therapeutics/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"krt-232","kind":"drug","name":"KRT-232","route":"/drugs/krt-232/"}],"trial":[{"id":"nct03669965","kind":"trial","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","route":"/trials/nct03669965/"},{"id":"nct04502394","kind":"trial","name":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","route":"/trials/nct04502394/"},{"id":"nct05797831","kind":"trial","name":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","route":"/trials/nct05797831/"}]}}